Neurocrine Bio. (NBIX) PT Raised to $145 at Mizuho

Mizuho analyst Vamil Divan raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $140.00) while maintaining a Neutral rating.

The analyst commented; "In our view, overall 2Q25 results were solid, with Ingrezza slightly ahead of sell-side expectations while Crenessity outperformed sell-side and buy-side targets. That said, we believe some investors expected a little more from Ingrezza and might be disappointed with Neurocrine lowering 2025 Ingrezza guidance (albeit a modest -$25M reduction at the midpoint) -- which might explain the modest weakness in the stock. For 2025, we maintain our Ingrezza sales forecast as our 2025 sales forecast is basically at the midpoint of new Ingrezza guidance. However, we increase our 2025 sales forecast for Crenessity considerably, from $91M to $223M given the better-than-expected and strong adoption trends (664 new patient start forms in 2Q25). As a result, we increase our PT from $140 to $145. We maintain our Neutral rating on valuation."

You May Also Be Interested In

• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• Pony AI Inc (PONY) PT Lowered to $17 at BofA Securities
• Freedom Capital Starts Hut 8 Mining Corp. (HUT) at Buy